1 Cycloserine for Treatment of Multidrug-Resistant Tuberculosis in China: A

2 Retrospective Observational Study

3

4 Yang Li^{1,*}, Fei Wang^{2,*}, Limin Wu³, Min Zhu⁴, Guiqing He⁵, Feng Sun¹, Qihui Liu¹, Xiaomeng

5 Wang², Wenhong Zhang¹

6

7

8 ¹ Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200032,

9 China

10 ² Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310006,

11 China

12 ³ Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang 310021, China

13 ⁴ Tuberculosis Treatment Center, Hangzhou Red Cross Hospital, Hangzhou 310003, China

14 ⁵ Department of Infectious Diseases, Wenzhou Center Hospital, Wenzhou 325000, China

15

16 * These authors contributed equally to this work.

17

18 **Emails:**

19 Yang Li: y_li11@fudan.edu.cn;

20 Fei Wang: feiwang@cdc.zj.cn;

21 Limin Wu: 2323533220@qq.com

22 Min Zhu: zhumindocto@163.com

23 Guiqing He: lalaliy@sina.com

24 Feng Sun: aaronsf1125@126.com

25 Qihui Liu: 08301010265@fudan.edu.cn

26 Xiaomeng Wang: xmwang@cdc.zj.cn

27 Wenhong Zhang: zhangwenhong@fudan.edu.cn

28

29

30 **Correspondence:** Xiaomeng Wang

31 E-mail: xmwang@cdc.zj.cn

32 Address: No.630 Xincheng Road, Binjiang District, Hangzhou, Zhejiang 310051, China

33 Fax: 057187115183

34 Tel: 86-13906525336

35

36

Abstract

Objectives

Cycloserine is crucial in multidrug-resistant tuberculosis (MDR-TB) treatment. Although extensive research has been carried out on MDR-TB, most researchers have not treated cycloserine in much detail. Therefore, we evaluate the efficacy and safety of cycloserine and seek to clarify the role of cycloserine for treatment of simple MDR-TB, pre-extensively drug-resistant tuberculosis (pre-XDR-TB), and extensively drug-resistant tuberculosis (XDR-TB).

Patients and methods

A retrospective observational study was performed in China. We determined the treatment outcome as the primary outcome for 144 cycloserine-treated and 181 cycloserine-nontreated patients according to the definitions of WHO. The proportion of patients with sputum-culture conversion and the frequency of adverse drug reactions related to cycloserine were assessed as well.

Results

Among 325 MDR-TB patients, 144 were treated with cycloserine and 100 (69.4%) out of 144 successfully completed treatment. Compared with patients in non-cycloserine group, the hazard ratio of any unfavorable treatment outcome was 0.53 (95%CI: 0.35–0.81, $P=0.003$). Culture conversion rate at the intensive phase was similar whether cycloserine was administered or not ($P=0.703$). Of the 144 patients treated with cycloserine, a total of 16 (11.1%) patients experienced side-effects related to cycloserine, including 7 patients who discontinued cycloserine permanently.

Conclusions

Cycloserine could be an attractive agent to treat MDR-TB. Its safety profile warrants use in the

59 most of MDR-TB cases. Cycloserine significantly improved the chance of favorable outcome for
 60 patients with simple MDR-TB but not pre-XDR-TB and XDR-TB. More aggressive regimens
 61 might be required for pre-XDR-TB or XDR-TB patients.

62

63 **KEYWORDS:** Cycloserine, multidrug-resistant tuberculosis, efficacy, safety, extensively
 64 drug-resistant tuberculosis, simple MDR-TB

65

Introduction

Tuberculosis (TB) has been a continuing threat throughout the ages. Since the early 1990s, the global outbreaks of multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis (TB) caused by organisms that are resistant to rifampicin and isoniazid, have been reported and it is generally accepted that resistance to these two potent anti-TB agents is associated with an increased probability of catastrophic treatment costs and poorer treatment outcomes. Furthermore, extensively drug-resistant tuberculosis (XDR-TB), defined as MDR-TB plus resistance to a fluoroquinolone and an injectable second-line drug, has recently emerged and threaten the public health on a worldwide scale(1). In 2016, there were an estimated 490000 new cases of MDR-TB and globally the second highest number of drug-resistant TB (DR-TB) cases came from China. The latest data from the World Health Organization (WHO) reported a treatment success rates of 54% for MDR-TB and only 30% for XDR-TB(2).

Cycloserine, a cyclic analogue to D-alanine, could target alanine racemase and D-alanine ligase, thus blocking the formation of bacterial cell wall(3). Cycloserine has been introduced in tuberculosis therapy since the late 1950s(4). Years later, Sommer *et al* found its potential for therapeutic intervention for chronic pulmonary tuberculosis(5). However, the neurological toxicity of cycloserine has been concerning clinicians and limiting its use widely. An earlier report described the neurological adverse effects of cycloserine that it would induce symptomatic seizures in approximately 10% patients(6). With more effective drugs like rifampicin discovered, cycloserine has been applicable only in the treatment of apparent or proved drug-resistant tuberculosis.

To implement tuberculosis control, WHO has published treatment guidelines for drug-resistant TB

in 1997 for the first time and cycloserine has been suggested since then as it shares no cross-resistance with other agents and might be valuable to prevent resistance to other active drugs(7). Cycloserine was classified as a Group 4 oral bacteriostatic second-line medication in the 2008 recommendations(8). A study from Turkey in 2011 reported their experience in treating MDR-TB that the overall success rate of treatment achieved to 77% with the use of intensive regimens which included cycloserine(9). Meanwhile, WHO guidelines for the treatment of drug-resistant TB was updated and suggested a stronger association with cure of cycloserine than para-aminosalicylic acid (PAS)(10). In 2016, WHO regrouped the anti-TB agents and cycloserine was included in Group C (other core second-line agents) together with ethionamide (or prothionamide), linezolid and clofazimine. Generally, two or more of Group C agents are to be included when designing the core MDR-TB treatment regimen and ethionamide (or prothionamide) and cycloserine are supposed to be selected in preference to linezolid and clofazimine(2), which means that cycloserine would be in MDR-TB treatment's starting line-up. However, the clinical studies which mainly focused on cycloserine, particular in East Asia patients, are scarce, as the use of cycloserine was not approved in China until recently. In addition, the role of cycloserine in the treatment of XDR-TB or pre-XDR-TB (defined as resistance to isoniazid and rifampicin plus any fluoroquinolone or one of the injectable drugs) is not clear-out. To light of the uncertainties, we aimed to provide sufficient details to evaluate the efficacy, tolerability and safety of cycloserine in MDR/pre-XDR/XDR-TB treatment using a sizable cohort of patients with MDR-TB from China.

Patients and methods

Study design and procedures

This retrospectively cohort study was performed at two hospitals located in Zhejiang Province, China initiated by the Zhejiang Disease Control and Prevention Center (CDC) who has set up routine drug resistance monitoring for TB since 1999(11). Patients aged above 18 who were diagnosed with active MDR-TB were recruited consecutively during March 2012 through December 2015 to obtain full follow-up information. Positive culture for *Mycobacterial tuberculosis* and resistance to isoniazid and rifampicin proven by drug-susceptibility testing were required at enrolment. Furthermore, the participants were included when their treatment therapies were adapted to WHO recommendations (2016 version). Patients were excluded when met any of the following criteria: (1) positive for HIV test; (2) history of seizure disorder, mental depression, or severe anxiety; (3) decline to participate in this study.

The following information were collected: sociodemographic characteristics, indicators of severity (symptoms and radiologic findings), previous treatment, drug-resistant profiles, and background treatment regimen. Culture and sputum conversion and chest X-rays were performed periodically for treatment outcomes evaluation. Moreover, adverse drug reactions were monitored and promptly managed during the entire treatment course.

Approval for collection of data was provided by the ethics committees of Zhejiang CDC. All patients provided written informed consent.

Definitions

MDR-TB was defined as tuberculosis caused by a strain as *M. tuberculosis* that was resistant to at least isoniazid and rifampicin. XDR-TB was MDR-TB that was also resistant to the fluoroquinolones and any of second-line injectable drugs (capreomycin, kanamycin and amikacin).

Pre-XDR-TB was MDR-TB that was resistant to either a fluoroquinolone or a second-line injectable drug, but not both. In the present study, we use the term simple MDR-TB to refer to those with resistance to just isoniazid and rifampicin and complicated MDR-TB to refer to those with additional resistance beyond isoniazid and rifampicin including pre-XDR-TB and XDR-TB. Standard treatment outcome definitions were applied according to the definitions and reporting framework for TB from WHO in 2013(12). Cured was defined as treatment completed without evidence of failure and three or more consecutive cultures were negative after the intensive phase. If bacteriological results were lacking (*i.e.* fewer than three cultures performed), the case was defined as treatment completed. Treatment failure was defined as treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of lack of conversion by the end of the intensive phase, or bacteriological reversion in the continuation phase after conversion to negative, or adverse drug reaction. Default was defined as interruption of treatment for at least 2 months not meeting the criteria for failure. This study used the following brief outcomes: favorable outcome was defined as cured and treatment completion; unfavorable outcome was defined as any failure, default or death while on treatment. When assessing the adverse drug reaction, we distinguished two types of side-effects: major side-effects and minor side-effects(13). The former referred to any adverse reactions that resulted in temporary or permanent discontinuation of anti-TB drugs, while the latter referred to those that only required dose adjustment and/or addition of concomitant treatment.

Drug susceptibility testing

Sputum culture on Löwenstein–Jensen medium or MGIT 960 were applied routinely. Phenotypic

drug susceptibility testing to two first-line drugs (rifampicin, isoniazid) and two second-line drugs (ofloxacin and kanamycin) was performed from the first positive *Mycobacterial tuberculosis* culture with the use of the proportion method and the result was compared with the standardised strains. The critical drug concentrations of rifampicin, isoniazid, ofloxacin, and kanamycin were 40, 0.2, 2, and 30 µg/ml respectively(14).

Data management and statistical analysis

The clinical data were collected through questionnaires and medical records by trained health workers. For the analysis, patients were divided into two cohorts according to the presence or absence of cycloserine in the background regimen (Cycloserine cohort *versus* Non-cycloserine cohort). Continuous variables were calculated as mean with standard deviation (SD) and median with interquartile range and were further compared by Mann-Whitney *U* test. Categorical data were presented as numbers (percentage) and were compared with the use of χ^2 test.

The primary outcome was the proportion of favorable treatment in each treatment cohort. Secondary outcome included the efficacy of cycloserine measured by the proportion of conversion within the intensive phase and safety and tolerability of cycloserine measured by the frequency of major and minor reactions.

For the primary outcome, all patients' treatment outcomes were identified according to the definitions described above by two clinicians blinded for the background regimen. And the proportion of each treatment outcome for two cohort were calculated. Considering the potential confounders, we further investigated the effect of cycloserine upon the treatment outcome by using a Cox proportional-hazards model. Furthermore, we did the specific subgroup analyses of

patients with different drug resistance patterns.

Two-tailed *P* value of less than 0.05 was considered statistically significant. All statistical calculations and analyses in this study were performed with the use of SPSS Statistics, version 22.0 (IBM).

Results

Study population

Enrolment of patients began in March 2012 and the follow-up for the last patient was performed by December 2017. A total of 582 patients were assessed for eligibility. 241 patients were excluded because their background regimens were not adapted to WHO recommendations (2016 versions) and 11 patients were excluded because the strains from their isolates were identified as nontuberculous mycobacteria. Moreover, three patients with HIV positive and two patients with mental illness in the control group were excluded as well. Consequently, 325 patients confirmed to have an organism resistant to both rifampicin and isoniazid were enrolled, 144 of whom were treated with cycloserine in their background regimen according to WHO guidelines for designated dosages of 500mg or 750mg per day (500mg for 38 patients weight less than 50kg; 750mg for 96 patients more than 50kg). All patients' background regimen included one of fluoroquinolones and only two patients in cycloserine group had not been treated with aminoglycosides as the initial treatment. Most of demographic and baseline clinical characteristics were comparable among two treatment cohorts except tuberculosis cavity being more frequent in the cycloserine group. The mean age was 42.9 years and approximately 70% of patients were male. 27.4% (89/325) patients were treated with at least one of fluoroquinolones or aminoglycosides more than 30 days before.

More details could be found in Table 1.

Treatment outcome

There was a trend approaching a level of significance in treatment outcome: 100 out of 144 (69.4%) cycloserine-treated patients achieved treatment success *versus* 108 out of 181 (59.7%) non-cycloserine-treated patients (χ^2 test, $P=0.089$, Table 2). The absence to sputum conversion at 6 months and severe adverse drug effects resulting in two or more drugs stoppage were the main reason for treatment failure; the relative responsibilities were 35.1% and 43.3% in the cycloserine group and 41.7% and 43.3% in the non-cycloserine group respectively. One patient was complicated by pulmonary infection and died on the eighteenth months of treatment. To reduce confounding bias, a Cox regression analysis was used and suggested that introduction of cycloserine to the standard drug regimen resulted in significantly less risk of unfavorable treatment outcomes (Hazard Ratio, [HR]: 0.58, 95% confidence interval [CI]: 0.35–0.81, $P=0.003$, Table 3).

Efficacy end-points assessment

Efficacy was mainly measured by sputum culture conversion and proved to be roughly similar between two groups. There was no difference in the proportion achieving sputum culture conversion at the end of intensive phase (117/144, 81.3% *versus* 144/181, 79.6%, $P=0.703$) or at the end of treatment (127/144, 88.2% *versus* 149/181, 82.3%, $P=0.142$) between the cycloserine group and non-cycloserine group. For those who had sputum culture conversion, the mean $\pm$ SD time to culture conversion in patients treated with cycloserine were longer than those without (90 $\pm$

121 days *versus* 59±61 days, $P=0.003$). With the use of Cox regression analysis, cycloserine also did not accelerate sputum culture conversion (HR: 1.057, 95%CI: 0.814–1.372, $P=0.679$).

Safety assessment

Overall, 132 of 144 patients (91%) in the cycloserine group and 161 of 181 patients (89%) in the non-cycloserine group had clinically significant adverse drug reactions. The most frequent adverse events were gastrointestinal effects (nausea and vomiting), arthralgia, liver injury and hypokalaemia in both two treatment groups (Figure 1). Among these 132 patients reporting adverse events in the cycloserine group, 37 (28%) experienced major adverse-effects, whereas 95 (72%) patients experienced minor side-effects. Adverse events attributed to cycloserine are shown in Table 4. Side-effects that were possibly or probably related to cycloserine appeared after a median of 71 days (range 10–331 days) of cycloserine treatment. A total of sixteen patients reported seventeen episodes related to cycloserine, including nine patients discontinued cycloserine temporarily or permanently. We observed eight episodes of headache and cycloserine was permanently withdrawn from the treatment regimen in two patients. Moreover, two cases of seizure, one case of depression, and two cases of anxiety were observed, with these events resulting in cycloserine discontinuation within the first six months of treatment. No suicidal ideation was observed.

Treatment outcomes stratified by resistance patterns

The treatment outcomes were further compared between two groups stratified by resistance patterns (Figure 2). Among simple MDR-TB patients, the proportion of treatment success in the

cycloserine group was higher than the non-cycloserine group, reaching statistical significance (68/85, 80.0% *versus* 73/117, 62.4%, $P=0.007$). For other strata, the treatment success rate in the cycloserine group was almost similar to patients who were not treated with cycloserine. Or rather, among pre-XDR-TB patients, the proportion achieving favorable outcome was 56.3% (27/48) in those receiving cycloserine *versus* 56.9% (29/51) in those treated without cycloserine ($P=0.951$); and among XDR-TB patients, the proportion of favorable outcome was 45.5% (5/11) and 46.2% (6/13), respectively ($P=0.973$). We also calculated the sputum conversion rate at six months and observed no significant difference between two groups regardless of the resistance patterns (data not shown). Moreover, a downward trend in favorable treatment outcome rate was observed with the increase in the extent of drug resistance in both groups.

Risk factors to unfavorable treatment outcomes

The associations between unfavorable treatment outcomes and each baseline variables were firstly assessed with univariate Cox regression model. Those variables with P value < 0.1 would be included into multivariate Cox regression model (Table 3). Using a Cox regression analysis, we found that a significant risk of unfavorable treatment outcomes related to age older than 60 years (HR: 2.61, 95%CI: 1.46–4.65; $P=0.001$), presence of cough before starting treatment (HR: 2.34, 95%CI: 1.07–5.11; $P=0.033$), and previous exposure to fluoroquinolones more than 30 days (HR: 1.71, 95%CI: 1.08–2.83; $P=0.024$) or resistance to fluoroquinolones proven by drug-susceptibility testing (HR: 1.92, 95%CI: 1.16–3.16; $P=0.011$).

Discussion

The research on tuberculosis treatment has witnessed a clear shift from drug-sensitive tuberculosis to drug-resistant tuberculosis, as more than half of patients with drug-resistant tuberculosis experience treatment failure owing to the weaknesses and intolerability of current treatment regimen for drug-resistant tuberculosis. To improve the treatment outcome, intensified research and innovation, the third pillar of WHO's Post-2015 Global Tuberculosis Strategy, has been emphasized(15). Safer, easier and shorter treatment regimens is a critical target that clinicians are moving forward to. The arrival of novel drugs like delamanid and bedaquiline has offered fresh opportunities(16)(17) but up to now, there are not enough new drugs to establish an entirely new regimen, so that the effective use of existing tools is urgently needed to combat tuberculosis.

In this study, we focus on cycloserine, an agent that would be added into the initial treatment regimen in priority for MDR-TB according to WHO recommendation, because the evaluation of this drug is greatly hampered by the lack of randomized controlled trials or cohort studies with a reliable outcome measure. To our knowledge, this is the first controlled study to seek to define or optimise the role of cycloserine in drug-resistant tuberculosis treatment. Our data reported an overall treatment success rate of 69.4% within 24 months in the patients treated with cycloserine. Previous studies suggested that the successful outcome rate ranged from 67.5% to 77.0%(18)(9)(19), almost in accordance with our results. There are several possible reasons to explain the slight differences. Firstly, the definition of treatment outcome has been updated and further emphasized the tolerability of the regimens which was likely to be underappreciated before. Secondly, some studies combined adjunctive therapy like surgical resection that resulted in improved treatment outcomes(9)(20). Moreover, the accelerated development of pre-XDR-TB and XDR-TB probably reduces the treatment success rate.

Furthermore, compared with the patients in the non-cycloserine group whose regimens mainly included PAS instead of cycloserine, it is suggesting a significant trending towards improved proportion of favorable treatment outcome after the introduction of cycloserine. Based on the current definition we applied, favorable treatment outcome should meet at least three requirements including sputum culture conversion within six months, no sputum reversion, and no severe adverse drug reactions requiring two or more drugs to be discontinued, which indicates that treatment outcome assessments need to integrate efficacy end-points and safety end-points.

Efficacy end-points in this study were mainly measured by time to and proportion of sputum culture conversion. Unlikely drug-susceptible tuberculosis, failure to sputum conversion rather than relapse or sputum reversion accounted for a great proportion of treatment failure(21), suggesting that the current regimens for MDR-TB might not show the strong sterilizing activity.

As for cycloserine, our study did not provide sufficient evidence that cycloserine could confer a benefit to culture conversion compared with other standardised treatment regimens. A possible explanation for these results may be that treatment of MDR-TB includes multiple drugs and an observational study without strict placebo controls hardly assesses the efficacy of a single agent.

Furthermore, a recent study (22) has showed that more than half of patients with the recommended dosage of 10mg/kg of cycloserine prescription had peak serum concentrations lower than the minimum inhibitory concentrations of the strains isolated from the corresponding patients, suggesting the personal need for adjusting dosages depending on the clinical pharmacokinetic and pharmacodynamic assessments(23).

Adverse drug reaction remains problematic during the treatment course for MDR-TB patients. By contrast with other anti-TB agents, ADR attributed to cycloserine was relatively uncommon with a

308 frequency of 11.1%. Therefore, cycloserine might be regarded as a safer alternative agent to those
309 with frequent severe side effects that tend to result in drug discontinuation and eventually
310 unfavorable clinical outcomes. Similar results were found in a meta-analysis that estimated the
311 frequencies of any ADR from cycloserine at 9.1% (95%CI: 6.4-11.7)(24). Neuropsychiatric
312 reactions, as expect, were representative of adverse effects of cycloserine since its central active
313 mechanism as a partial NMDA-agonist and high brain-blood-barrier permeability(25). In this
314 study, headache was one of the most common side-effects of cycloserine reported by patients
315 although almost headache resolved quickly with an adjustment in the dose or the temporary
316 discontinuation of cycloserine. Seizure was rare, mainly associated with high dosages (especially
317 with concentrations levels exceeding 40 µg/ml)(26), co-administration of fluoroquinolones, and
318 alcoholism(25), but all led to the withdrawal of cycloserine in this study. Psychiatric disturbances
319 were also described on rare occasions in our study but were more complicated to manage for
320 clinicians. In detail, depression or anxiety might be partly attributable to the inadequate social
321 support and lacking of confidence owing to previous poor treatment outcomes, such as the patient
322 (P89) of depression who had been infected with *Mycobacterium Tuberculosis* for more than eight
323 years complicated with post-tuberculosis destroyed lung and complained of unbearable arthralgia
324 during the treatment. The major challenge is the lack of reference standard against which to
325 evaluate psychiatric events. However, the current psychiatric reactions to cycloserine is mainly
326 based on case reports (27) and further controlled studies are needed to validate it scientifically.

327 To explore the role of cycloserine for patients with different resistance patterns, we did a subgroup
328 analysis and observed the significant improvement in treatment outcomes related to cycloserine in
329 simple MDR-TB patients, which was hindered greatly in complicated MDR-TB patients. The

findings from subgroup analyses suggested cycloserine alone are of less benefit without more effectiveness drugs as linezolid for complicated MDR-TB patients(13), indicating the requirement for reprioritization of cycloserine when managing highly resistant forms of tuberculosis. The treatment of complicated MDR-TB, especially XDR-TB, has been considered as a conundrum facing clinicians. In accordance, this study identified the limited beneficial impact of the standardised five-drug regimen in complicated MDR-TB, calling for new or repurposed agents to effectively eradicate extensive drug-resistant *Mycobacterium Tuberculosis*.

This retrospective study has several limitations. First, the major limitations derive from the observational study design which precluded us from controlling of confounding bias well and looking at some important topics, especially pharmacokinetic and pharmacodynamic assessments of cycloserine. Secondly, some strains isolated from patients were missing and thus we did not perform the drug susceptibility testing to cycloserine. Moreover, as cycloserine had not been approved in China until 2014, its availability and affordability require further evaluation.

To summarize, introduction of cycloserine improved the overall favorable outcome of MDR-TB patients. Cycloserine is considered a better-tolerated agent with infrequent adverse side-effects characterized with neuropsychiatric reactions. For simple MDR-TB patients, we believe our results support the use of cycloserine in the setting of correct patient assessment and monitoring.

And for complicated MDR-TB patients, more effective treatment options may be considered.

Acknowledgements

We thank all patients for affording their treatment profiles and all health care workers who

participated in this effort.

Financials

This study is funded by Zhejiang-National Committee of Health and Family Planning Co-Sponsored Project (WKJ-ZJ-07).

References:

1. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. *Emerg Infect Dis* 13:380–387.
2. World Health Organization WH, Global Tuberculosis Programme. 2016. WHO treatment guidelines for drug-resistant tuberculosis : 2016 update. Who 56.
3. Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. 2011. Structure of the *Mycobacterium tuberculosis* D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. *Antimicrob Agents Chemother* 55:291–301.
4. Epstein IG, Nair KGS, Boyd LJ. 1955. Cycloserine, a New Antibiotic, in the Treatment of Human Pulmonary Tuberculosis: a Preliminary Report. *Antibiot Med* 1:80–93.

- 374 5. Somner AR, Brace AA. 1962. Ethionamide, pyrazinamide and cycloserine used successfully in
375 the treatment of chronic pulmonary tuberculosis. *Tubercle* 43:345–360.
- 376 6. Cohen AC. 1969. Pyridoxine in the prevention and treatment of convulsions and neurotoxicity
377 due to cycloserine. *Ann N Y Acad Sci* 166:346–349.
- 378 7. Crofton Sir, J, Chaulet P, Maher D. 1997. GUIDELINES FOR THE MANAGEMENT OF
379 DRUG-RESISTANT TUBERCULOSIS. *Trans R Soc Trop Med Hyg* 92.
- 380 8. World Health Organization. 2008. Guidelines for the programmatic management of
381 drug-resistant tuberculosis Guidelines for the programmatic management of drug-resistant
382 tuberculosis. *World Heal Organ* 12–185.
- 383 9. Tahaoğlu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Ozmen I, Kapakli N. 2001. The
384 treatment of multidrug-resistant tuberculosis in Turkey. *N Engl J Med* 345:170–4.
- 385 10. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA,
386 Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH,
387 Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A,
388 Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D,
389 Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A,
390 Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.
391 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011
392 update. *Eur Respir J* 38:516–528.
- 393 11. Wang X, Fu Q, Li Z, Chen S, Liu Z, Nelson H, Yang Q, Jia Z, Dye C. 2012. Drug-resistant
394 tuberculosis in zhejiang province, China, 1999-2008. *Emerg Infect Dis* 18:496–498.
- 395 12. 2013. Who revised definitions and reporting framework for tuberculosis. *Eurosurveillance* 18.

396 13. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi
397 E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C. 2008. A retrospective
398 TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant
399 tuberculosis. *Eur Respir J* 34:387–393.

400 14. Who. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line
401 antituberculosis drugs World Health Organization. World Health 1–20.

402 15. Lönnroth K, Raviglione M. 2015. The WHO’s new end tb strategy in the post-2015 era of the
403 sustainable development goals. *Trans R Soc Trop Med Hyg*.

404 16. Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De
405 Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P. 2018. Early safety
406 and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with
407 drug-resistant tuberculosis in Armenia, India, and South Africa: A retrospective cohort study.
408 *Lancet Infect Dis*.

409 17. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V,
410 Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E,
411 van Heeswijk RPG, Dannemann B. 2014. Multidrug-Resistant Tuberculosis and Culture
412 Conversion with Bedaquiline. *N Engl J Med* 371:723–732.

413 18. Prasad R, Verma SK, Sahai S, Kumar S, Jain a. 2006. Efficacy and Safety of Kanamycin ,
414 Ethionamide , PAS and Cycloserine in Multidrug-resistant Pulmonary Tuberculosis Patients.
415 *Indian J Chest Dis Allied Sci* 48:183–186.

416 19. Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri M V., Farnia P, Javanmard
417 P, Mansouri D, Velayati AA. 2008. Outcome of treatment of MDR-TB patients with

418 standardised regimens, Iran, 2002-2006. *Int J Tuberc Lung Dis* 12:750–755.

419 20. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara
420 Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HSF,
421 Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M,
422 Palacios E, Sanchez E, Sloutsky A, Becerra MC. 2008. Comprehensive treatment of
423 extensively drug-resistant tuberculosis. *N Engl J Med* 359:563–574.

424 21. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov G V., Via LE, Van Der
425 Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T,
426 Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova E V., Kim HJ, Kim CK, Kazenny
427 BY, Jou R, Huang WL, Ershova J, Erokhin V V., Diem L, Contreras C, Cho SN, Chernousova
428 LN, Chen MP, Caoili JC, Bayona J, Akksilp S. 2014. Extensive drug resistance acquired during
429 treatment of multidrug-resistant tuberculosis. *Clin Infect Dis* 59:1049–1063.

430 22. Yu X, Zeng X, Shi W, Hu Y, Nie W, Chu N, Huang H. 2018. Validation of Cycloserine
431 Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in
432 Beijing, China. *Antimicrob Agents Chemother* 2018/01/10. 62.

433 23. Hung WY, Yu MC, Chiang YC, Chang JH, Chiang CY, Chang CC, Chuang HC, Bai KJ. 2014.
434 Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in
435 Northern Taiwan. *Int J Tuberc Lung Dis* 2014/06/07. 18:601–606.

436 24. Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. 2013. Safety of
437 cycloserine and terizidone for the treatment of drug-resistant tuberculosis: A meta-analysis. *Int*
438 *J Tuberc Lung Dis*.

439 25. Schade S, Paulus W. 2016. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.

440 Int J Neuropsychopharmacol 2015/09/14. 19.

441 26. Holmes CX, Martin GE, Fetterhoff KI. 1959. The role of the cycloserine (seromycin) blood

442 level in the treatment of pulmonary tuberculosis and the prevention and control of cycloserine

443 (seromycin) toxicity. Dis Chest 1959/12/01. 36:591–593.

444 27. Sharma B, Handa R, Nagpal K, Prakash S, Gupta PK, Agrawal R. 2014. Cycloserine-induced

445 psychosis in a young female with drug-resistant tuberculosis. Gen Hosp Psychiatry 36.

446

Table 1 Characteristics of multidrug resistant tuberculosis cases treated with or without cycloserine.

	Cycloserine (N=144)	No Cycloserine (N=181)	<i>P</i> value
Age (years)			
Mean $\pm$ SD	44.0 $\pm$ 12.7	41.7 $\pm$ 13.1	0.067
Median (IQR)	45 (35–54)	40 (31–53)	
Female sex	45 (31.3%)	51 (28.2%)	0.546
Bodyweight (kg)			
Mean $\pm$ SD	54.2 $\pm$ 8.8	53.8 $\pm$ 7.8	0.541
Median (IQR)	54 (48–60)	52.5 (49–60)	
Medical history of DM	21 (14.6%)	19 (10.5%)	0.265
Tuberculosis symptoms			
Fever	28 (19.4%)	19 (10.5%)	0.023
Fatigue	26 (18.1%)	42 (23.2%)	0.257
Haemoptysis	26 (18.1%)	35 (19.3%)	0.769
Dyspnoea	2 (1.4%)	6 (3.3%)	0.309
Cough	127 (88.2%)	151 (83.4%)	0.225
Chest radiograph			
Presence of cavity	113 (78.5%)	117 (64.6%)	0.006
Bilateral involvement	103 (71.5%)	139 (76.8%)	0.279
Previous TB medications			
Fluoroquinolones	36 (25.0%)	41 (22.7%)	0.694
Aminoglycosides	22 (15.3%)	25 (13.8%)	0.709
Drug Resistant Patterns			0.569
MDR-TB	85 (59.0%)	117 (64.6%)	
pre-XDR-TB	48 (33.3%)	51 (28.2%)	
XDR-TB	11 (7.6%)	13 (7.2%)	
Most frequently used anti-TB drugs in the Background Regimen			
Fluoroquinolones			
Levofloxacin	87 (60.4%)	155 (85.6%)	
Moxifloxacin	57 (39.6%)	26 (14.4%)	
Aminoglycosides			
Capreomycin	43 (29.9%)	13 (7.2%)	
Kanamycin	23 (16.0%)	125 (69.1%)	
Amikacin	76 (52.8%)	43 (23.8%)	
Pyrazinamide	140 (97.2%)	162 (89.5%)	
Prothionamide	136 (94.4%)	180 (99.4%)	
Para-aminosalicylic acid	8 (5.6%)	152 (83.5%)	

Data are presented as n(%), unless otherwise stated.

Abbreviations: SD, standard deviation; IQR, interquartile range; DM, diabetes mellitus; TB, tuberculosis; MDR, multidrug resistant; pre-XDR, pre-extensive drug resistant; XDR, extensive drug resistant

Table 2 Comparison of treatment outcomes of multidrug-resistant/extensively drug resistant tuberculosis cases treated with or without cycloserine.

	Cycloserine (N=144)	No Cycloserine (N=181)	<i>P</i> value
Treatment Success	100 (69.4%)	108 (59.7%)	0.089
Cure	94 (65.3%)	106 (58.6%)	
Treatment Completion	6 (4.1%)	2 (1.1%)	
Treatment Failure	37 (25.7%)	60 (33.2%)	
Fail to conversion at 6 months	13 (9.0%)	26 (14.4%)	
Reversion	8 (5.6%)	9 (5.0%)	
Adverse drug reactions	16 (11.1%)	25 (13.8%)	
Death	0 (0.0%)	1 (0.5%)	
Default	7 (4.9%)	12 (6.6%)	

Table 3 Cox regression analysis of potential independent variables associated with unfavorable treatment outcome in multidrug resistant tuberculosis cases

Variables	Univariate Cox Regression		Multivariate Cox Regression	
	Crude HR (95%CI)	<i>P</i> value	Adjusted HR (95%CI)	<i>P</i> value
Age ≥ 60 years	2.23 (1.32–3.66)	0.003	2.61 (1.46–4.65)	0.001
Cough	3.11 (1.45–6.68)	0.004	2.34 (1.07–5.11)	0.033
Fever	1.83 (1.17–2.87)	0.008	1.57 (0.95–2.61)	0.079
Bilateral involvement	1.92 (1.18–3.10)	0.008	1.45 (0.88–2.38)	0.141
Previous fluoroquinolones treatment*	1.80 (1.20–2.70)	0.004	1.71 (1.08–2.83)	0.024
Previous aminoglycosides treatment*	1.71 (1.10–2.69)	0.019	1.01 (0.58–1.76)	0.969
Resistance to fluoroquinolones	2.55 (1.57–4.14)	<0.001	1.92 (1.16–3.16)	0.011
Resistance to aminoglycosides	2.61 (1.37–4.99)	0.004	1.35 (0.68–2.70)	0.391
Cycloserine treatment [†]	0.66 (0.45–0.96)	0.030	0.53 (0.35–0.81)	0.003
Pyrazinamide treatment [†]	0.38 (0.22–0.66)	0.001	0.70 (0.20–2.41)	0.570
Clarithromycin treatment [†]	2.32 (1.44–3.72)	<0.001	1.97 (0.91–4.25)	0.085
High-dose isoniazid treatment [†]	2.23 (1.20–4.15)	0.012	0.58 (0.15–2.25)	0.430
Amoxicillin–clavulanate treatment [†]	4.11 (1.30–12.99)	0.016	5.07 (1.42–18.17)	0.013

Abbreviations: HR, Hazard Ratio; CI, confidence interval

* Treated with fluoroquinolones or aminoglycosides more than 30 days before.

[†] Treated with cycloserine, pyrazinamide, clarithromycin, high-dose isoniazid or amoxicillin-clavulanate as the baseline regimen.

Table 4 Side effects associated with cycloserine or requiring to withdraw cycloserine.

Patient ID	Age (years)	Daily CS doses*	Interval time† (days)	Side effects	Relationship to CS	Doses Adjustment or Stoppage
P9	48	500mg	119	abdominal distension	Unlikely related	De-escalation to 250mg
P80	52	750mg	115	headache	Probably related	temporarily stopped (2 days)
P89	51	500mg	132	depression	Probably related	permanently stopped
P90	39	750mg	10	seizures	Possibly related	permanently stopped
P96	28	750mg	164	headache	Probably related	permanently stopped
P106	56	500mg	127	seizures	Possibly related	permanently stopped
P109	57	500mg	16	headache	Probably related	No adjustment
			16	peripheral neuropathy	Possibly related	No adjustment
P110	61	500mg	80	tremor	Possibly related	permanently stopped
P112	63	500mg	41	rash	Possibly related	No adjustment
P115	45	750mg	331	headache	Possibly related	De-escalation to 500mg
P117	49	500mg	50	headache	Probably related	permanently stopped
P119	45	750mg	28	anxiety	Possible related	temporarily stopped (1 month)
P123	38	750mg	58	headache	Probably related	No adjustment
P124	35	750mg	154	headache	Probably related	De-escalation to 500mg
P127	37	750mg	71	headache	Probably related	No adjustment
P143	39	750mg	21	anxiety	Probably related	permanently stopped

*Daily CS doses refer to the doses in the background regimen.

†Interval time from start of therapy to appearance of side effects (days).

Abbreviation: CS, cycloserine; mg, milligram.

Figure 1 Proportions of favorable treatment outcome, according to the resistance pattern among patients treated with and without cycloserine.
Abbreviation: MDR-TB, multidrug resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis.

Figure 2 Adverse drug reactions in patients with and without cycloserine treated for multidrug-resistant tuberculosis in China. Adverse drug reactions which were associated with cycloserine are marked in sky blue (Minor adverse effects) or navy blue (Major adverse effects).